{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:40:25Z","timestamp":1756280425142,"version":"3.44.0"},"reference-count":31,"publisher":"BMJ","issue":"9","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["DTB"],"published-print":{"date-parts":[[2016,9]]},"abstract":"<jats:p>Hidradenitis suppurativa is a recurring chronic inflammatory debilitating skin disease of the hair follicle that usually presents with painful, deep-seated and inflamed lesions in the apocrine gland-bearing areas of the body. The lesions often progress to become chronic with purulent discharge, sinus formation and scarring. Hidradenitis suppurativa is associated with systemic comorbidities, including metabolic syndrome and inflammatory bowel disease.<jats:sup>1<\/jats:sup> Long-term treatment is often necessary and requires coordination between primary care, dermatologists and surgeons. However, there is a lack of good quality evidence and a paucity of authoritative guidance on treatment strategies. In this article, we review the diagnosis and management of hidradenitis suppurativa and discuss some new developments, including the use of cytokine modulators.<\/jats:p>","DOI":"10.1136\/dtb.2016.9.0423","type":"journal-article","created":{"date-parts":[[2016,9,1]],"date-time":"2016-09-01T22:26:49Z","timestamp":1472768809000},"page":"102-105","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Management of hidradenitis suppurativa"],"prefix":"10.1136","volume":"54","member":"239","published-online":{"date-parts":[[2016,9,1]]},"reference":[{"key":"2025082700005875000_54.9.102.1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12966"},{"key":"2025082700005875000_54.9.102.2","doi-asserted-by":"crossref","unstructured":"Collier F , et al . Diagnosis and management of hidradenitis suppurativa. Br Med J 2013; 346: f2121.","DOI":"10.1136\/bmj.f2121"},{"key":"2025082700005875000_54.9.102.3","doi-asserted-by":"crossref","unstructured":"Ingram JR , et al . Interventions for hidradenitis suppurativa. Cochrane Database Syst Rev 2015; 10: CD010081. DOI:10.1002\/14651858.CD010081.pub2 [Last assessed as up-to-date 13 August 2015].","DOI":"10.1002\/14651858.CD010081.pub2"},{"key":"2025082700005875000_54.9.102.4","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.255"},{"key":"2025082700005875000_54.9.102.5","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1016\/j.jaad.2014.09.012","article-title":"Hidradenitis suppurativa is a systemic disease with substantial co-morbidity burden","volume":"71","author":"Shlyankevich","year":"2014","journal-title":"J Am Acad Dernatol"},{"key":"2025082700005875000_54.9.102.6","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03476.x"},{"key":"2025082700005875000_54.9.102.7","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.jaad.2015.07.045","article-title":"Pathophysiology of hidradenitis suppurativa: an update","volume":"73","author":"Prens","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2025082700005875000_54.9.102.8","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/bjd.13777","article-title":"Hidradenitis suppurativa and metabolic syndrome: a comparative cross-sectional study of 3207 patients","volume":"173","author":"Shalom","year":"2015","journal-title":"Br J Dermatol"},{"key":"2025082700005875000_54.9.102.9","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1001\/jamadermatol.2015.6264","article-title":"Risk of major cardiac events and all-cause mortality in patients with hidradenitis suppurativa","volume":"152","author":"Egeberg","year":"2016","journal-title":"JAMA Dermatology"},{"key":"2025082700005875000_54.9.102.10","doi-asserted-by":"publisher","DOI":"10.1159\/000269836"},{"key":"2025082700005875000_54.9.102.11","unstructured":"Hurley H . Axillary hyperhidrosis, apocrine bromohidrosis, hidradenitis suppurativa, and familial benign pemphigus: surgical approach. In: Roenigh R (Ed). Dermatologic surgery. New York: Marcel Dekker, 1989; 729\u201339."},{"key":"2025082700005875000_54.9.102.12","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.jaad.2015.07.046","article-title":"Pain management in patients with hidradenitis suppurativa","volume":"73","author":"Horvath","year":"2015","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"2025082700005875000_54.9.102.13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.298.6665.28"},{"key":"2025082700005875000_54.9.102.14","doi-asserted-by":"crossref","unstructured":"Gulliver W , et al . Evidence-based approach to the treatment of hidradenitis suppurativa\/acne inversa, based on the European guidelines for hidradenitis suppurativa. Rev Endocr Metab Disord [Epub ahead of print] 1 February 2016; DOI: 10.1007\/s11154-016-9328-5.","DOI":"10.1007\/s11154-016-9328-5"},{"key":"2025082700005875000_54.9.102.15","unstructured":"Humira 40\u2005mg\/0.4\u2005ml Pre-filled Syringe and Pre-filled Pen. Summary of product characteristics, UK. AbbVie Limited, June 2016."},{"key":"2025082700005875000_54.9.102.16","unstructured":"Medicines and Healthcare products Regulatory Agency. Oral retinoids: pregnancy prevention\u2014reminder of measures to minimise teratogenic risk. Drug Safety Update 2013; 6 (11): H1 [online]. Available: https:\/\/www.gov.uk\/drug-safety-update\/oral-retinoids-pregnancy-prevention-reminder-of-measures-to-minimise-teratogenic-risk [Accessed 17 August 2016]."},{"key":"2025082700005875000_54.9.102.17","unstructured":"Dapsone tablets 100mg BP. Summary of product characteristics, UK. Actavis UK Limited December 2015."},{"key":"2025082700005875000_54.9.102.18","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/j.1524-4725.2011.02186.x","article-title":"Hidradenitis suppurativa: surgical and other management techniques","volume":"38","author":"Ellis","year":"2012","journal-title":"Dermatol Surg"},{"key":"2025082700005875000_54.9.102.19","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use, 2015. Assessment report: Humira [online]. Available: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000481\/WC500195564.pdf [Accessed 17 August 2016]."},{"key":"2025082700005875000_54.9.102.20","doi-asserted-by":"crossref","unstructured":"Ingram JR , et al . Development of core outcome sets in hidradenitis suppurativa: a systematic review of outcome measure instruments to inform the process. Br J Dermatol [Epub ahead of print] 12 February 2016; DOI: 10.1111\/bjd.14475.","DOI":"10.1111\/bjd.14475"},{"key":"2025082700005875000_54.9.102.21","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1983.tb02150.x"},{"key":"2025082700005875000_54.9.102.22","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70272-5"},{"key":"2025082700005875000_54.9.102.23","doi-asserted-by":"publisher","DOI":"10.1159\/000228334"},{"key":"2025082700005875000_54.9.102.24","doi-asserted-by":"publisher","DOI":"10.1159\/000228337"},{"key":"2025082700005875000_54.9.102.25","doi-asserted-by":"crossref","unstructured":"Jemec G , et al . Efficacy and safety of adalimimab in patients with moderate to severe hidradenitis suppurativa: results from PIONEER II, a phase 3 randomised placebo-controlled trial. J Am Acad Dermatol 2015; 72 (suppl1): AB45.","DOI":"10.1016\/j.jaad.2015.02.192"},{"key":"2025082700005875000_54.9.102.26","unstructured":"National Institute for Health and Care Excellence, 2016. Adalimumab for treating moderate to severe hidradenitis suppurativa [online]. Available: https:\/\/www.nice.org.uk\/guidance\/ta392\/resources\/adalimumab-for-treating-moderate-to-severe-hidradenitis-suppurativa-82602906813637 {Accessed 17 August 2016]."},{"key":"2025082700005875000_54.9.102.27","unstructured":"The Scottish Medicines Consortium, 2016. Adalimumab (Humira) [online]. Available: http:\/\/www.scottishmedicines.org.uk\/SMC_Advice\/Advice\/1143_16_adalimumab_Humira\/adalimumab_Humira [Accessed 17 August 2016]."},{"key":"2025082700005875000_54.9.102.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.06.050"},{"key":"2025082700005875000_54.9.102.29","first-page":"155","article-title":"Alitretinoin: a useful agent in the treatment of hidradenitis suppurativa, especially in women of child-bearing age","volume":"150","author":"Verdolini","year":"2015","journal-title":"Giornale Italiceno di Dermatologica"},{"key":"2025082700005875000_54.9.102.30","doi-asserted-by":"publisher","DOI":"10.1159\/000329023"},{"key":"2025082700005875000_54.9.102.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2012.04668.x"}],"container-title":["Drug and Therapeutics Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/dtb.2016.9.0423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T07:01:10Z","timestamp":1756278070000},"score":1,"resource":{"primary":{"URL":"https:\/\/dtb.bmj.com\/lookup\/doi\/10.1136\/dtb.2016.9.0423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9]]},"references-count":31,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2016,9,8]]},"published-print":{"date-parts":[[2016,9]]}},"alternative-id":["10.1136\/dtb.2016.9.0423"],"URL":"https:\/\/doi.org\/10.1136\/dtb.2016.9.0423","relation":{},"ISSN":["0012-6543","1755-5248"],"issn-type":[{"type":"print","value":"0012-6543"},{"type":"electronic","value":"1755-5248"}],"subject":[],"published":{"date-parts":[[2016,9]]}}}